July 24, 2015 /
An MS Patients Story
July 16, 2015 – MIAMI (CBSMiami) – “I have MS, but MS doesn’t have me.”
That quote
comes from former Miami Dolphin cornerback Don McNeal.
comes from former Miami Dolphin cornerback Don McNeal.
A player perhaps most remembered for a tackle he missed in Super Bowl XVII is now fighting multiple sclerosis.
The incurable disease has begun to sap his mobility.
McNeal is now forced to get around on a scooter given to him by his in-laws. McNeal, ever the optimist, refuses to feel down about it.
“Coach Don Shula always told me no matter what, always show your class,” said McNeal. “That’s what I’m trying to do here.”
McNeal, now 57, will head back to his native Atmore, Alabama next week.
The town will host a walk and run in his honor to raise funds in the fight against MS.
in his honor to raise funds in the fight against MS.
McNeal, a man of deep religious faith, still spends three days a week at Dade Christian School in Miami Lakes. He’s the former pastor of its adjoining church, and his wife Rhonda serves as the school’s admissions officer.
Rhonda serves as the school’s admissions officer.
“He has such a good spirit,” said McNeal’s wife Rhonda. “He never complains, and even picks me up when I have a bad day. His positive attitude is why everyone still wants him around here.”
McNeal believes repeated NFL concussions brought on his ailment. He is among a slew of former players suing the league for damages.
McNeal wants empathy, not sympathy.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
.===========================================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
Categories
Latest Blog Posts
- People Wait an Average of 50 Days to See a Neurologist, and People with MS Wait Even Longer: What Can We Do to Improve Access to MS Care?
- Key Findings on GLP-1 Use in MS
- Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
- Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
- This Blood Test Tracks MS Activity? (Octave Explained)
- Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
- Will Medicare Pay for a Mobility Scooter?
- Vagus nerve stimulation (VNS)
- Vitamin D Deficiency in Adults: Symptoms, Treatments, and Related Health Conditions
- How to Get Through an MRI if You’re Claustrophobic
- How MS Can Affect Your Oral Health
- Signs of multiple sclerosis show up in blood years before symptoms, study finds
- MS patients less likely to have Alzheimer’s, study finds
- APOE4 gene variant linked to greater nerve damage in MS: Study
- High Epstein-Barr antibody levels over time may aid MS diagnosis
- Stopping Ocrevus in stable MS doesn’t seem to raise 2-year risk, study finds
- Online Survey: Stress and MS – from the National MS Society
- High-Altitude Gene Helps Heal Myelin Damage
- Talking Biosimilars – Unlocking Patient access through coordinated action
- Beyond One Drug: What the Tolebrutinib Decision Teaches Us About Progressive MS Trials.
